Start the conversation with a senior partner

where to start

Start with the value story that matters most

Bring us a market entry, access, medical or regulatory challenge. We will identify where your global story needs local translation and why waiting is costly: the first GCC submission cohorts are setting the precedents you will be judged against.

Entry Point

GCC Diagnostic

A focused assessment of the regulatory landscape, partner viability, and where your global story needs local access, medical and regulatory translation.

Defined Scope

Focused Workstream

One defined scope, senior-led an HTA dossier, a payer negotiation, an advisory board, and a launch readiness plan.

Full Programme

Integrated Regional Programme

Access, medical and regulatory workstreams aligned end-to-end for GCC market entry and launch include expert-network validation with former payers and regional clinicians.

Get in touch

In a 45-minute first session, a senior partner will scan your asset’s landscape, map the localisation gaps and recommend where to start.

Email Address

contact@veridianlifesciences.com

Phone Number

+971 5614 85416

Address

South Tower, Dubai Science Park, Dubai, UAE

LinkedIn

Stay up to date on our LinkedIn

Get GCC Access Insights

Practical thinking on registration, HTA, pricing and clinical adoption across the GCC, plus details of upcoming Veridian events.

Ajaz Rashid

Medical affairs & scientific communications

Over 30 years in medical affairs, scientific communications and clinical research in global, regional and local roles. Successful track record in leading people and teams to develop and deliver scientific narratives, programmes and content with demonstrable HCP impact across multiple therapeutic areas including respiratory, immunology, oncology, CV, metabolic, neurology and hepatology.

Dr. Rashmi Hegde

Medical affairs

30 years delivering 80+ Life Sciences product & vaccine regulatory approvals for launches across therapies and geographies. Expertise in Pharmacovigilance, Medical, Clinical, patient affairs, and medical governance. Optimized MA & MSL capabilities, focusing on executional excellence. Achieved 100% PV compliance across 33 global affiliates

Dr. Laura Jotimliansky

Medical affairs & clinical research

30+ years in pharma across multiple TAs and geographies. Internal Medicine and Clinical Pharmacology training with deep LATAM and Middle East focus. At GSK, led regional teams and built Oncology structure across Emerging Markets. Previously at BMS and Roche.

Dr. Elif Coskuncay

Medical affairs

25+ years spanning pharma, clinical practice, and strategic medical affairs at global, regional, and local levels. Therapeutic expertise in oncology, cardiovascular, metabolic, respiratory, rare diseases, and vaccines. Successfully launched life-saving therapies including immuno-oncology in emerging and developed markets.

Rafa Al Khalifa

Market access & stakeholder engagement

Healthcare strategy consultant specializing in specialty pharmacy, market access, patient support programs, health economics, quality, and compliance. UAE MOHAP-registered pharmacist. Led the first ACHC-accredited specialty pharmacy outside the US. FIP SAPS Executive Committee member; represented FIP at the World Health Assembly and COP29. Co-Founder of EcoRx UAE.

Dr. Claudia Soares

Rwe, heor & business intelligence

Physician with MSc/PhD in Epidemiology & Biostatistics and a Master’s in Business Intelligence (focused on AI in healthcare). Over 18 years of experience across academia, government, and the pharmaceutical industry in R&D, Health Outcomes, and Medical Affairs. Led global, regional, and local projects in clinical development, launch planning, epidemiology, health outcomes, real-world data (RWD), and evidence generation, with a strong track record of impact in emerging markets.

Dr. Ali AlHammad

Heor & market access

HEOR expert with strong background in market access, patient-reported outcomes, and medical research. Proven track record developing strategic brand plans for successful launches in Saudi Arabia. Deep understanding of the Saudi healthcare system, translating complex economic data into actionable insights for payers.

Safinaz Issa

Regulatory affairs & market access

Senior Regulatory, Government Affairs & Market Access Executive with 25+ years of leadership across Pfizer, GSK, Sanofi Genzyme, Novartis, Eisai, and Eli Lilly. Led 1,000+ filings and market access strategies across 40+ markets in MEA, Europe, and North America. Expertise spans regulatory strategy and intelligence, health authority engagement, compliance, lifecycle management, and complex product launches across rare diseases, neuroscience, oncology, and medical devices.

Dr. Razia Hussain

Director, Medical Affairs

Senior Medical Affairs and Clinical Research leader with 25+ years of international pharmaceutical experience across Oncology, Immunology, Cardiovascular, Respiratory, HIV, Hepatology, and Specialty Medicine. Led Medical Affairs teams in China and clinical research operations globally, delivering registration studies, evidence generation, pre-launch readiness, and RWE programmes. Developed medical excellence capabilities adopted as global best practices, led a major cardiovascular RWE study in the Middle East, and established a regional pharmacovigilance hub for Africa. Strong track record in medical strategy, cross-functional leadership, stakeholder engagement, and building high-performing teams.

Fayaz Aziz

Managing Director, HTA/HEOR and Market Access

Senior health economics, market access, and medical affairs leader with 25+ years of international experience spanning industry, government, academia, and consultancy across R&D, EU, Emerging Markets, and the Middle East. Led HEOR strategy and medical excellence across 30+ markets at GSK, delivered HTA submissions to NICE and SMC at Pfizer UK, and founded a global HEOR Academy that trained 2,000+ professionals. 15+ years in the GCC, with early career foundations as a public health scientist at the England Department of Health, health policy training at LSE, and doctoral research at LSHTM on AI governance in HTA decision-making.